MacroGenics Company Profile (NASDAQ:MGNX)

About MacroGenics (NASDAQ:MGNX)

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MGNX
  • CUSIP: N/A
  • Web:
  • Market Cap: $652.43 million
  • Outstanding Shares: 36,798,000
Average Prices:
  • 50 Day Moving Avg: $17.74
  • 200 Day Moving Avg: $18.14
  • 52 Week Range: $14.36 - $31.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.50
  • P/E Growth: 0.01
Sales & Book Value:
  • Annual Revenue: $12.08 million
  • Price / Sales: 54.01
  • Book Value: $6.31 per share
  • Price / Book: 2.81
  • EBITDA: ($140,860,000.00)
  • Net Margins: -1,216.51%
  • Return on Equity: -56.81%
  • Return on Assets: -48.97%
  • Current Ratio: 8.37%
  • Quick Ratio: 8.37%
  • Average Volume: 203,802 shs.
  • Beta: 2.77
  • Short Ratio: 16.21

Frequently Asked Questions for MacroGenics (NASDAQ:MGNX)

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by $0.09. The business earned $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The company's quarterly revenue was down 97.9% compared to the same quarter last year. During the same period last year, the firm earned $1.12 EPS. View MacroGenics' Earnings History.

When will MacroGenics make its next earnings announcement?

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for MacroGenics.

Where is MacroGenics' stock going? Where will MacroGenics' stock price be in 2017?

11 brokerages have issued twelve-month target prices for MacroGenics' shares. Their predictions range from $21.00 to $44.00. On average, they expect MacroGenics' stock price to reach $31.56 in the next year. View Analyst Ratings for MacroGenics.

What are analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:

  • 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (10/10/2017)
  • 2. BTIG Research analysts commented, "Based upon the 4Q16 earnings call hosted last week and our follow-up conversation with management, we present an outline of expected activities during 2017. The majority of the MGNX portfolio will be entering or expanding Phase 1 studies during 2017, which will weigh potential clinical catalysts towards 2H2017 and early 2018. The most significant identified clinical read-out during 2017 will likely be the futility analysis from the Margetuximab pivotal study. We reiterate our Buy Rating but lower our Price Target to $28 from $35 as we push out Margetuximab sales expectations until 2021. A summary of events for 2017 is charted on Page 2 of this report." (3/6/2017)
  • 3. Cowen and Company analysts commented, "MGNX reported 4Q16 results and provided a pipeline update." (3/1/2017)
  • 4. Instinet analysts commented, "We are initiating coverage of MacroGenics with a Buy rating and $41 target price. We recommend accumulating MGNX shares in 2017, as we anticipate several data sets across programs, specifically for the company's B7-H3 franchise. We expect data cross multiple tumor types from ongoing basket trials of both enoblituzumab and bispecific counterpart MGD009 to define initial market opportunities that represent upside to current estimates." (3/1/2017)
  • 5. Stifel Nicolaus analysts commented, "Management's relatively quiet 4Q16 earnings announcement/call was expected following the comprehensive pipeline update provided at the December 2016 R&D Day. The specific timing and magnitude of incremental news flow from both wholly-owned and partnered programs throughout FY17 still remains a bit uncertain ' but we anticipate the finalization of dose and administration schedules for a variety of DART programs to allow for the initiation of dose expansion cohorts in both FY17 and beyond. SOPHIA enrollment appears to remain on track and a newly-implemented trial amendment allowing for Kadcyla-na??ve patients should facilitate the pace of enrollment and eventually expand the addressable market opportunity. We continue to find valuation attractive here. Reduced target price of $42 (previously $51) reflects higher FY17 and forward-year OpEx ' coupled with reduced longer-term collaborative revenue estimates." (3/1/2017)

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:

  • Paulo F. Costa, Independent Chairman of the Board
  • Scott Koenig M.D., Ph.D., President, Chief Executive Officer, Director
  • James Karrels MBA, Chief Financial Officer, Senior Vice President, Secretary
  • Ezio Bonvini M.D., Senior Vice President - Research, Chief Scientific Officer
  • Atul Saran, Senior Vice President, General Counsel
  • Eric Risser, Senior Vice President - Business Development and Portfolio Management and Chief Business Officer
  • Thomas Spitznagel Ph.D., Senior Vice President - Bio Pharmaceutical Development and Manufacturing
  • Jon Wigginton, Senior Vice President - Clinical Development and Chief Medical Officer
  • Lynn Cilinski, Vice President, Controller, Treasurer
  • Karen Jean Ferrante M.D., Independent Director

How do I buy MacroGenics stock?

Shares of MacroGenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MacroGenics stock can currently be purchased for approximately $17.73.

MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MacroGenics (NASDAQ:MGNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $31.56 (77.98% upside)
Consensus Price Target History for MacroGenics (NASDAQ:MGNX)
Price Target History for MacroGenics (NASDAQ:MGNX)
Analysts' Ratings History for MacroGenics (NASDAQ:MGNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Stifel NicolausReiterated RatingBuy$34.00HighView Rating Details
9/11/2017WedbushReiterated RatingOutperform$44.00HighView Rating Details
9/1/2017SunTrust Banks, Inc.Reiterated RatingBuy$26.00HighView Rating Details
8/7/2017Morgan StanleyLower Price TargetEqual Weight$22.00 -> $21.00LowView Rating Details
8/4/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
3/31/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$26.00HighView Rating Details
3/6/2017BTIG ResearchReiterated RatingBuy$35.00 -> $28.00N/AView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/AView Rating Details
1/25/2017Citigroup Inc.Lower Price TargetNeutral$32.00 -> $24.00N/AView Rating Details
6/14/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
5/19/2016Leerink SwannReiterated RatingOutperform$47.00N/AView Rating Details
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for MacroGenics (NASDAQ:MGNX)
Earnings by Quarter for MacroGenics (NASDAQ:MGNX)
Earnings History by Quarter for MacroGenics (NASDAQ MGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.89)N/AView Earnings Details
8/2/2017Q2 2017($1.05)($1.14)$15.82 million$1.70 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.99)($1.08)$5.88 million$2.06 millionViewListenView Earnings Details
2/28/2017Q416($0.86)($1.00)$10.65 million$5.00 millionViewListenView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)$10.95 million$2.85 millionViewN/AView Earnings Details
8/5/2015Q2($0.44)($0.71)$13.88 million$6.72 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.87($0.58)$58.29 million$71.28 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.36)($0.69)$12.41 million$5.48 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.42)($0.14)$9.43 million$18.38 millionViewListenView Earnings Details
8/5/2014Q2 2014($0.29)($0.44)$11.22 million$9.22 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.09)($0.12)$18.00 million$14.72 millionViewN/AView Earnings Details
11/12/2013$0.15$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MacroGenics (NASDAQ:MGNX)
2017 EPS Consensus Estimate: ($4.16)
2018 EPS Consensus Estimate: ($3.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.18)($0.83)($1.03)
Q2 20174($1.17)($0.83)($1.03)
Q3 20174($1.21)($0.86)($1.04)
Q4 20174($1.23)($0.88)($1.06)
Q1 20181($0.97)($0.97)($0.97)
Q2 20181($0.88)($0.88)($0.88)
Q3 20181($0.91)($0.91)($0.91)
Q4 20181($0.93)($0.93)($0.93)
(Data provided by Zacks Investment Research)


Dividend History for MacroGenics (NASDAQ:MGNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MacroGenics (NASDAQ:MGNX)
Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 84.47%
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/5/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.00View SEC Filing  
4/19/2017Jon Marc WiggintonSVPSell15,000$20.00$300,000.00View SEC Filing  
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.00View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.68View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.00View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.00View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.84View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MacroGenics (NASDAQ:MGNX)
Latest Headlines for MacroGenics (NASDAQ:MGNX)
Loading headlines, please wait.



MacroGenics (MGNX) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.